METHOD OF APPLYING INFORMATION ON A COMPLEX GROUP OF BIOMARKERS FOR DIAGNOSING A MALIGNANT LUNG TUMOR IN SUBJECT, DIAGNOSTIC KIT AND COMPUTER SYSTEM USING IT Russian patent published in 2019 - IPC G01N33/574 G06F17/18 G16H10/40 G16H50/70 G16H50/30 

FIELD: medicine.

SUBSTANCE: group of inventions refers to oncology, and can be used for diagnosing a malignant lung tumour in a subject. Method includes the following stages. 1) using a computer system to obtain a diagnosis model of malignant lung tumour. Model is established using: data of expression level of individual biomarkers in a complex group of biomarkers, measured from biological sampling samples, consisting of patients with malignant lung tumour and people without malignant lung tumour, or their processed data B_ki, where k is an index for individual biomarkers and i is an index for separate biological sampling samples; 2) a computer system is used to obtain data of expression level of individual biomarkers measured in a biological sample of a subject, or their processed data B_k, or data of expression level of individual biomarkers, or their processed data B_k and subject's age; 3) a computer system is used to determine whether a malignant lung tumour has been detected in a subject. Computer system uses data obtained from the subject by referring to the model M. Above complex group of biomarkers includes a cancer-embryonic antigen (CEA), human epididymis protein (H4), apolipoprotein A-II (ApoA2), transthyretin (TTR), soluble adhesion molecule of type 1 vascular endothelium (sVCAM-1) and expressed and secreted by normal T-cells upon activation, regulated with ligand 5 activation of chemokine (motive C-C) (RANTES). Kit for diagnosing a malignant lung tumour contains antibodies which specifically bind to CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES as separate biomarkers in a complex group of biomarkers. Kit for diagnosis of a malignant lung tumour using a complex group of biomarkers, containing the following: at least six receptor sites; and six or more antibodies corresponding to biomarkers which are located on at least six receptor sites, respectively, and specifically bind to separate biomarkers in a complex group of biomarkers. Six or more antibodies include antibodies which specifically bind to separate biomarkers of CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES. Kit for diagnosing a malignant lung tumour is used to determine whether a malignant lung tumour has been detected in a subject by referring to the M model for diagnosing a malignant lung tumour. Model is obtained by using the expression data of individual biomarkers measured from biological samples of a sample consisting of patients with a malignant lung tumour and people without a malignant lung tumour, or their processed data B_ki, where k is an index for individual biomarkers and i is an index for separate biological sample samples. Diagnosis is carried out by inputting into model of data of expression level of individual biomarkers measured from biological sample of subject or their processed data B_k, or data of expression level of individual biomarkers or their processed data B_k and subject's age. Computer system for diagnosing a malignant lung tumour using a complex group of biomarkers involves the following: 1) a communication portion for obtaining a malignant tumour diagnosis model, wherein the model is constructed using the expression data of individual biomarkers in a complex group of biomarkers, measured from biological sample samples, consisting of patients with malignant lung tumour and people without malignant lung tumour, or their processed data B_ki, where k is an index for individual biomarkers and i is an index for individual biological sampling samples, and obtaining the expression data of the individual biomarkers measured from the biological sample of the subject, or their processed data B_k, or data of expression level of individual biomarkers or their processed data B_k and age of subject's age; 2) a processor for determining whether a malignant lung tumour has been detected in a subject using the obtained subject data by accessing the model. Complex group of biomarkers for diagnosing malignant lung tumour includes separate biomarkers CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES.

EFFECT: group of inventions provides automated diagnosis of malignant lung tumour, as well as increases effectiveness of diagnosis of malignant lung tumour by using a complex group of biomarkers CEA, HE4, ApoA2, TTR, sVCAM-1 and RANTES.

13 cl, 11 tbl, 11 dwg